Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $164,000 Stock Position in Cencora, Inc. $COR

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 96.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 500 shares of the company’s stock after selling 14,354 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Cencora were worth $164,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in COR. Tema Etfs LLC acquired a new position in Cencora during the third quarter worth $2,038,000. Swmg LLC grew its position in shares of Cencora by 34.5% in the 3rd quarter. Swmg LLC now owns 5,937 shares of the company’s stock valued at $1,951,000 after acquiring an additional 1,523 shares during the period. Forum Financial Management LP grew its position in shares of Cencora by 12.1% in the 3rd quarter. Forum Financial Management LP now owns 1,525 shares of the company’s stock valued at $477,000 after acquiring an additional 165 shares during the period. Hemington Wealth Management increased its stake in shares of Cencora by 12.0% during the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after purchasing an additional 35 shares during the last quarter. Finally, Sonoma Allocations LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $235,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Wells Fargo & Company lifted their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Evercore ISI set a $400.00 price target on Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Barclays assumed coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $379.50.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

Shares of NYSE COR opened at $342.11 on Tuesday. The firm has a market cap of $66.37 billion, a P/E ratio of 43.03, a price-to-earnings-growth ratio of 1.60 and a beta of 0.66. The business’s 50 day moving average is $349.92 and its 200-day moving average is $318.78. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 1-year low of $233.61 and a 1-year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.